Clinical research policy, take two
This article was originally published in The Gray Sheet
Both federally funded and private trials would be affected by CMS's latest 1proposal to clarify its coverage of "usual patient care" for beneficiaries participating in clinical studies. Unlike the current policy, the proposal allows study sponsors and principle investigators to self-certify that their studies meet agency criteria in order to receive coverage. Standards require registration on ClinicalTrials.gov, public release of study results within two years after the end of data collection, and discussion of how results are or are not expected to generalize to the Medicare population. CMS issued the proposal July 19. It addresses "confusion and ambiguity" that became apparent after the agency first proposed a revision to the original policy in April (2"The Gray Sheet" July 16, 2007, p. 8). Comments on the new proposal are due Aug. 18, and CMS hopes to finalize the policy in October...
You may also be interested in...
Major revisions to CMS' policy on covering clinical research costs were put on hold July 9 in response to stakeholder demands for more input
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.